Kezar Life Sciences, Inc

4000 Shoreline Ct Ste 300
South San Francisco, CA 94080

Kezar Life Sciences, Inc. is a biopharmaceutical company based in South San Francisco, CA, dedicated to developing innovative protein-targeting approaches for the treatment of chronic diseases. With a focus on regulating cellular function, Kezar is advancing novel, first-in-class small molecule therapies that selectively inhibit specific proteins involved in disease activation. By targeting multiple drivers of disease, their unique approaches have the potential to provide broad treatment effects across a range of chronic conditions.

Kezar's pipeline includes Zetomipzomib (KZR-616), a selective immunoproteasome inhibitor aimed at modulating the immune system to treat autoimmune diseases, and KZR-261, a protein secretion inhibitor designed to halt the proliferation of diseases in oncology and autoimmunity. Committed to improving patient outcomes, Kezar is actively seeking collaborative and innovative individuals to join their team in developing breakthrough treatments for autoimmune diseases and cancer.

Generated from the website

Own this business?
See a problem?

You might also like

Napo Pharmaceuticals, Inc
Drugs acting on the respiratory system, Drugs and drug proprietaries

Napo Pharmaceuticals, Inc

Napo Pharmaceuticals, Inc. is a San Francisco-based company dedicated to developing and commercializing prescription medicines that provide essential supportive care for individuals undergoing treatment for diseases like cancer. Their mission is to improve the comfort, quality of life, and dignity of patients experiencing treatment-related gastrointestinal distress, particularly overactive bowel symptoms such as chronic diarrhea, urgency, and incontinence. Napo Pharmaceuticals is currently focused on their Phase 3 pivotal OnTarget trial of Mytesi crofelemer, a preventative treatment for chemotherapy-induced overactive bowel, with comprehensive results expected in Q1 2024. They also support investigator-initiated studies exploring the potential of crofelemer for rare disease indications like short bowel syndrome and microvillus inclusion disease. Napo Pharmaceuticals takes pride in their responsible harvesting practices, sourcing their medicines from plants in rainforest regions. Their prescription medicines work through a novel mechanism of action, inhibitory modulation of two secretory chloride ion channels in the gastrointestinal tract. The company is committed to uncovering medical solutions to serve those in need, advancing their understanding through high-quality research conducted by external investigators. Environmental sustainability and social responsibility are paramount to Napo Pharmaceuticals, as they prioritize the responsible harvesting of their products and share benefits with the local communities that contribute to their mission.Generated from the website
United StatesCaliforniaSouth San FranciscoKezar Life Sciences, Inc

Partial Data by Infogroup (c) 2025. All rights reserved.